Previous 10 | Next 10 |
IDEAYA Biosciences, Inc. Reports Third Quarter 2020 Financial Results and Provides Business Update - IDE397, a potential best-in-class MAT2A inhibitor for patients with solid tumors having MTAP deletion, targeting an IND-filing in December 2020 - PARG and Pol Theta programs ...
IDEAYA to Participate in Upcoming November 2020 Investor Relations Events PR Newswire SOUTH SAN FRANCISCO, Calif., Nov. 2, 2020 SOUTH SAN FRANCISCO, Calif. , Nov. 2, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA), an oncology-focused precisi...
Ideaya Biosciences (IDYA) has entered into a target and biomarker discovery partnership with the Sellers Laboratory at the Broad Institute of MIT and Harvard.The partnership will utilize the CRISPR paralog screening platform to evaluate functionally redundant paralogous genes (result of gene ...
IDEAYA Announces Partnership With The Broad Institute And Advancement Of Synthetic Lethality Programs And Platform - The partnership with the Sellers Laboratory at the Broad Institute of MIT and Harvard will utilize the Broad CRISPR paralog screening platform for Synthetic Letha...
IDEAYA Biosciences (IDYA) expands its clinical trial collaboration and supply agreement with Pfizer (PFE) with a new study evaluating the combination of IDE196, a protein kinase inhibitor, and crizotinib, a cMET inhibitor, in patients with GNAQ or GNA11 mutation-positive solid tumors, includi...
IDEAYA Biosciences (IDYA) has expanded its previous trial collaboration and supply agreement with Pfizer for the evaluation of former' sponsored combination study of IDE196, a Protein Kinase C inhibitor, and latter' crizotinib, a cMET inhibitor, in patients with solid tumors having GNAQ ...
IDEAYA and Pfizer Expand Clinical Trial Collaboration and Supply Agreement to Evaluate Clinical Combination of IDE196 and Crizotinib in Solid Tumors Harboring GNAQ or GNA11 Mutations PR Newswire SOUTH SAN FRANCISCO, Calif., Sept. 24, 2020 SOUTH SAN FRANCISCO, Calif...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...
U.S. markets are closed for the Labor Day holiday More news on: Eli Lilly and Company, CVS Health Corporation, Bristol-Myers Squibb Company, , Top stock market news, Tech stocks news, Consumer stocks news, News on ETFs, Read more ...
LOS ANGELES, CA / ACCESSWIRE / August 31, 2020 / LD Micro today announced the final list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online. Registration details and the company schedule can be seen here: https://ld500.ldmicro.co...
News, Short Squeeze, Breakout and More Instantly...
IDEAYA Biosciences Inc. Company Name:
IDYA Stock Symbol:
NASDAQ Market:
IDEAYA Biosciences Inc. Website:
IDEAYA Biosciences to Participate in Upcoming August 2024 Investor Relations Event PR Newswire SOUTH SAN FRANCISCO, Calif. , July 29, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery an...
2024-07-10 16:15:02 ET RBC Capital analyst issues OUTPERFORM recommendation for IDYA on July 10, 2024 02:51PM ET. The previous analyst recommendation was Outperform. IDYA was trading at $37.33 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
2024-07-10 16:00:03 ET Gregory Renza from RBC Capital issued a price target of $61.00 for IDYA on 2024-07-10 14:51:00. The adjusted price target was set to $61.00. At the time of the announcement, IDYA was trading at $37.33. The overall price target consensus is at $35.3...